Company intelligence / Profile preview

NanoEcho

Ownership: Private
Employees: ~7
Development stage: Other

Overview

NanoEcho has developed a fully functional imaging device that combines nanotechnology with modern ultrasound to improve the diagnosis of early rectal cancer by detecting spread to nearby lymph nodes. The system has completed product development and received approval from the Swedish Medical Products Agency to begin clinical trials focused on nanoparticle dose confirmation. The company aims for CE marking submission by end of 2027 and plans initial market entry in Sweden and Europe

Therapeutic areas: Oncology
Modalities: Nanoparticle (as a diagnostic agent)Device (medical imaging device)
Industry: Medical Imaging

Partnerships

Planned partnerships with distributors/medical technology companies for sales; no major pharma or biotech partnerships disclosed yet

Beyond the preview

Go deeper on NanoEcho.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoEcho.

Explore the full profile